Jefferies stays Buy on Nektar Therapeutics (NKTR) after Rezpeg data hits upside estimates, sees 10-30% stock move into Ph3
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
